Krystal Biotech VYJUVEK revenue rises 24%
Share
- Krystal Biotech reported Q2 VYJUVEK revenue of $119.2 million, up 24% from the prior-year period.
- Krystal Biotech shares were down 7.03% at $341.12 in premarket trading following the results.
- The company expects several pipeline updates and VYJUVEK launches in Spain and Italy before year-end.
Krystal Biotech (NASDAQ:KRYS) reported Q2 VYJUVEK revenue of $119.2 million, up 24%, and net income of $54.8 million.
Revenue increased from $96 million, while diluted EPS rose to $1.79 from $1.29 and gross margin reached 95%.
Krystal maintained $175–$195 million expense guidance and said Spain and Italy launches remain planned before year-end.
Following the announcement, Krystal Biotech's share price was down 7.03% at $341.12 in premarket trading.
Krystal expects updates for KB803, KB407, KB111 and intratumoral KB707 during the second half of 2026.
The company held $1.1 billion in cash and investments, while cumulative VYJUVEK revenue reached $965.9 million.
Frequently asked questions
SEO metadata
Slug:
Meta title:
Frequently asked questions
More from United States
Cummins earnings surge to $1.14 billion as sales climb 13%
Six Flags reveals $1.17 billion Q3 revenue amid $366 million loss
EPAM Systems reports $1.43B Q3 revenue, expands buyback to $1.8B
Molson Coors Q3 sales fall 1.6% to $2.93 billion
ACI Worldwide reports $427 million in Q3 revenue, above forecast
Planet Fitness Q3 revenue skyrockets 9% to $360 million
